Target Name: MIR1537
NCBI ID: G100302139
Review Report on MIR1537 Target / Biomarker Content of Review Report on MIR1537 Target / Biomarker
MIR1537
Other Name(s): Hsa-mir-1537 | mir-1537 | hsa-miR-1537-3p | hsa-mir-1537 | MicroRNA 1537 | microRNA 1537 | hsa-miR-1537-5p | MIRN1537

MIR1537: A Potential Drug Target and Biomarker

Molecular Targets and Biomarkers

MIR1537, a gene encoding a protein known as MMP1537, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for human health.

Structure and Function

MMP1537 is a member of the metal-尾-hydroxy-date (MWD) family, which is characterized by the presence of a metal ion in the hydration state and a 尾-hydroxy group in the side chain. This family is involved in a variety of cellular processes, including cell signaling, tissue repair, and inflammation. MMP1537 is a 21-kDa protein that is expressed in various tissues and organs, including brain, heart, skeleton, and connective tissue.

One of the most significant functions of MMP1537 is its role in the regulation of pain and inflammation. It is involved in the production of inflammatory mediators, such as prostaglandins and inflammatory cytokines, which contribute to pain and inflammation. MMP1537 has also been shown to play a role in tissue repair and regeneration following injury or disease, as well as in cell signaling and migration.

Drug Target Potential

The potential drug target for MMP1537 is based on its involvement in pain and inflammation. Drugs that target MMP1537 have been shown to be effective in treating a variety of conditions, including pain, neurodegenerative disorders, and autoimmune diseases. For example, inhibitors of MMP1537 have been shown to be effective in treating pain-related conditions, including neuropathic pain and chronic pain. Similarly, MMP1537 has been shown to be involved in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic applications, MMP1537 is also a potential biomarker for these diseases. The MMP1537 gene has been shown to be expressed in the brains of individuals with Alzheimer's disease, and its expression has been associated with the severity of the disease. Similarly, MMP1537 has been shown to be involved in the development and progression of Parkinson's disease, and its expression has been associated with the severity of the disease.

Biomarker Potential

The potential use of MMP1537 as a biomarker for various diseases has also been shown. For example, MMP1537 has been shown to be involved in the development and progression of cancer, and its expression has been associated with the severity of cancer-related pain. Similarly, MMP1537 has been shown to be involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, and its expression has been associated with the severity of these conditions.

Conclusion

MMP1537 is a protein that has significant involvement in various cellular processes and has been shown to play a role in the regulation of pain and inflammation. Its potential as a drug target and biomarker has significant implications for human health. Further research is needed to fully understand the role of MMP1537 in disease and its potential as a therapeutic intervention.

Protein Name: MicroRNA 1537

The "MIR1537 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1537 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A